Pharmaceuticals company Fermenta Biotech announced Q1FY26 results Q1FY26 Consolidated Revenue Rs 145 crore, up 79% YoY. Consolidated EBITDA for Q1FY26 Rs 37 crore, up 922% YoY. PAT: Rs 21.6 crore vs Rs 5.9 crore loss during Q1FY25. EPS: Rs 7.49 for Q1FY26. Prashant Nagre, Managing Director, said: “Continuing our financial and operational turnaround of FY25, we delivered exceptional performance this quarter with strong YoY growth in revenue and EBITDA, driven by robust volume and price expansion across our human and animal nutrition segments. Fermenta’s strategic initiatives, including partnerships with NIFTEM-T and GAIN, strengthen our market position for sustained future growth." Result PDF